PharmaTalkRadio

Jeffrey Weber, Deputy Director at Laura and Isaac Perlmutter Cancer Center and Co-director of Melanoma Program and Head of Experimental Therapeutics at NYU Langone Medical Center, discusses the day to day management of, and the science around, IO adverse events that may help us understand how these drugs work. Including: The need to educate physicians about management of immune related adverse eve...

The BioCentury Report on Industry Trends covers how companies and academic investigators are driving innovations within immuno-oncology, including new targets, modalities and technologies, to address some of the field's biggest challenges. Some topics include: The broadening trend to harness the innate and adaptive arms of the immune system for immunotherapiesNew cell types beyond CAR-T and tradit...

IO360° brings together science, clinical and business under one roof to accelerate treatments to fight a wider range of cancers. This brief podcast gives you an overview on what you can expect at IO360°. The three-day summit features 10 plenary sessions with over 80 speakers and includes ten plus hours of networking. There will be over 450 attendees. Key benefits: Access to KOLs driving the scienc...

The 8th Annual Partnership Opportunities in Drug Delivery (PODD) event will take place on October 18-19, 2018. PODD is designed with 3 purposes: To present a strategic level program for pharma and biotech biz development professionals with a thorough overview of the latest drug delivery technologies available along with an update on deals and opportunities. To provide drug delivery with a platform...

Can you imagine coming from a family of 21 kids in a small remote village in Africa with no running water or electricity and one day a snake bite changes your entire future and you end up a PhD student in WInston-Salem, NC?  In this remarkable story, our guest Goodwell Nzou, PhD candidate in molecular medicine at the Institute at Wake Translation Science tells Valerie Bowling, Executive Director,...

Podcast guest, Elise Felicione, who is currently a Scientific Collaborator at the Scripps Translational Science Institute is playing an integral role under the direction of Dr Eric Topol on a nation-wide initiative from the NIH. The initiative is called All Of Us, a US Precision Medicine program that aims to enroll a million Americans and follow them for 10 years, during which time participants wi...

During his graduate work, Dr Benjamine Liu observed the many bottlenecks that get in the way of clinical trials slowing the development of new treatments for patients. This challenge inspired him to launch Trialspark. Trialspark partners with doctors to create FDA compliant trial sites within their existing practices (like Airbnb), unlocking the 98% of patients and doctors not involved in trials t...

Patients are at the center of research and their data is the foundation for clinical innovation. However, significant barriers exist that inhibit the secure and efficient sharing of patient data. In this podcast, Craig Lipset, Head of Clinical Innovation, Pfizer, Munther Barra, Head of New Clinical Paradigm, Pfizer and Aditya Kudumala, Principal, Deloitte discuss blockchain as a catalyst to signif...

This 8 minute podcast gives you an overview on what to expect from the 8th annual DPharm conference. DPharm is the annual event in the US to get the best access to innovative ideas, especially disruptive ones, to advance clinical trials with a view to reducing the burden to patients and investigators. DPharm 2018 is dedicated to all things digital, data science, patient data ownership and new appr...

Welcome to the 5th annual Mobile in Clinical Trials podcast. In this quick fire podcast, you will get a brief overview on what to expect. The conference takes place in Boston on Sept 24th, the day before DPharm. It is researched and produced by the Conference Forum and is chaired by:  Daniel Karlin, MD Assistant Professor of Psychiatry, Tufts University and Former Head of Clinical, Informatics, an...

Rational Combinations 360° addresses business aspects, clinical advancements and scientific data in IO combination strategies. The rapid advancement in our understanding of human cancer immunity and immunotherapy combinations is nearly impossible for individual scientists to comprehend. Only together, as an engaged and interactive scientific community, can we hope to enable a patient’s immune syst...

How to Innovate in the Drug Delivery Space What does the innovation process look likeThe barrier to the innovation process and how to overcomethemSummary of disease spaceGood design and engineering practicesHow to salvage something that goes wrong? How do you find the unknown unknowns? Does it feel right? Uri Baruch Head of Drug Delivery, Cambridge Design Partnership This talk was given at the 201...

Opening talk at Drug Delivery West, 2018 Key Trends in Drug Delivery: Expert Perspective Randall Mrsny, PhD Professor's Chair, Department of Pharmacy and Pharmacology, University of Bath

Patients as Partners Day 2 Session How FARA and Horizon Pharma Partnered to Improve Clinical Development and Trial Design-Case Study This session will feature how the Friedreich’s Ataxia Research Foundation collaborated with Horizon Pharma on aspects of clinical development and trial design to better understand patients living with the disease and how to better develop medicine to help manage thei...

This talk was given at the Patients as Partners 2018 Meeting There are many frameworks and models that exist from various organizations on aspects of patient engagement and may be challenging to navigate through when applying to your own initiatives. In this session, Takeda will walk the audience through how they used multiple patient engagement frameworks to create an internal R&D Patient Eng...

This talk was given at the Patients as Partners 2018 Meeting How Patient Research Advocates are Driving R&D: A Patient Case Study In this session, patient and research advocate, Geraldine Blavat will walk the audience through 10 steps on how patient input is integrated through the entire clinical development continuum including: Developing the Study Concept Secure Funding Preparing the Study P...

John Patton, PhD, Chief Executive Officer and Chairman with Dance Biopharma and Ann Daugherty, PhD, Senior Manager, Drug Delivery with Genentech present the closing talk at Drug Delivery West, held May 21-22, 2018 in San Francisco.  In this talk they discuss the lessons learned from drug delivery, what to be aware of in the future, and how to improve drug delivery methods.  The next conference in...

Nanotechnology Keynote Address given by Omid Farokhzad, MD, Professor, Harvard Medical School and Director, Center for Nanomedicine, Brigham and Women's Hospital Omid Farokhzad is an inventor of more than 145 issued / pending patents. These for the launch of four biotechnology companies: BIND Therapeutics (acquired by Pfizer) Selecta Biosciences, Tarveda Therapeutics (formerly Blend Therapeutics)...

Panel: Utilizing a Device Platform Technology across Multiple Therapeutic Categories Most pharma and biotech companies realize the need and benefit of having a platform device technology. The challenge then becomes figuring out how to utilize the device to deliver different types of drugs for various indications such as rheumatoid arthritis, cancer, and rare diseases. Moderator: Paul Jansen Former...

The Keynote was given at Partnerships Opportunities in Drug Delivery 2017 by Lars Rebein Sorensen Former President and CEO, Novo Nordisk with  Barbara Lueckel, PhD Global Business Development Director Roche Partnering Innovation, Roche  

The expert panel of scientific leaders from industry will discuss current formulation and delivery challenges for therapeutic areas (ophthalmology, immunology, oncology infectious disease, and neurodegenerative area disorders). Each panelist will address a specific disease area and discuss the role of drug delivery in the treatment of disease. The panel will also cover currently available delivery...

The expert panel will address the scientific and business challenges and opportunities in this space. Panelists will discuss the difficult nature of providing therapies for diseases of the CNS, covering both device and chemistry-enabled technologies. They will also address questions such as:  Can devices take us where chemistry has not? What advances being made in the field of chemis conjugation t...

Drug Delivery Needs in Oncology Due to the increasing number of parenteral biologic therapies that are administered intravenously, the already high pressure on infusion capacity and healthcare resources is expected further increase. A change from intravenous to subcutaneous dosing has been shown to reduce dosing complexity and overall drug administration related costs. There is keen interest in te...

Track 2: Clinical Operations for IO Trials This section is designed for clinical trial operation executives who want to learn what it takes to execute an IO clinical trial. This is an excellent opportunity to walk through the building blocks of IO clinical trial operations and discuss pitfalls and lessons learned. Plenary Chair: Andy Lee, SVP, Head of Global Clinical Trial Operations, Merck   This...

Building Blocks of IO Trials: This talk will consist of 7 perspectives that identify operational aspects of IO trials, including a patient perspective, site management, 3rd party component, clinical supply chain, a PI perspective, data management and project management. The collaborative talk concludes with a panel discussion and Q&A.   This Discussion was presented at the 2018 Immuno-Oncology...